PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21989294-1 2011 BACKGROUND: Na+/I- symporter (NIS)-mediated iodide uptake allows radioiodine therapy for thyroid cancer. Iodine-131 65-76 solute carrier family 5 member 5 Homo sapiens 12-28 23404348-2 2013 However, the optimal timing of radioiodine application following hNIS gene transfer remains unknown. Iodine-131 43-54 solute carrier family 5 member 5 Homo sapiens 77-81 23404348-10 2013 In conclusion, the optimal timing for radioiodine administration is day 2 after adenovirus-mediated hNIS gene transfer into anaplastic thyroid carcinoma. Iodine-131 50-61 solute carrier family 5 member 5 Homo sapiens 124-128 23420532-2 2013 Non-thyroid cancers may be treated with radio-iodine following transfection with the human sodium/iodide symporter (hNIS) gene. Iodine-131 40-52 solute carrier family 5 member 5 Homo sapiens 116-120 23420532-4 2013 The present study used GFAP promoter-modulated expression of the hNIS gene in an experimental model of radioiodine-based treatment for malignant glioma. Iodine-131 103-114 solute carrier family 5 member 5 Homo sapiens 65-69 23037808-0 2012 A steep radioiodine dose response scalable to humans in sodium-iodide symporter (NIS)-mediated radiovirotherapy for prostate cancer. Iodine-131 8-19 solute carrier family 5 member 5 Homo sapiens 81-84 23037808-2 2012 We have extended the use of NIS-mediated radioiodine therapy to prostate cancer. Iodine-131 41-52 solute carrier family 5 member 5 Homo sapiens 28-31 22355179-1 2012 The selective increase of Na(+)/I(-) symporter (NIS)-mediated active iodide uptake in thyroid cells allows the use of radioiodine I(131) for diagnosis and targeted treatment of thyroid cancers. Iodine-131 118-129 solute carrier family 5 member 5 Homo sapiens 26-46 22234102-3 2011 NIS mediated radioiodine transport to breast cancers is under active investigation due to its potential therapeutic utility. Iodine-131 13-24 solute carrier family 5 member 5 Homo sapiens 0-3 22790962-1 2012 Anaplastic thyroid cancer is an extremely aggressive disease resistant to radioiodine treatment because of loss of sodium iodide symporter (NIS) expression. Iodine-131 74-85 solute carrier family 5 member 5 Homo sapiens 140-143 22412937-3 2012 Ad5/3-hTERT-hNIS expresses hNIS for imaging of transgene expression and for treatment of infected tumors by radioiodine. Iodine-131 108-119 solute carrier family 5 member 5 Homo sapiens 12-16 22412937-5 2012 Survival of mice treated with intravenous Ad5/3-hTERT-hNIS significantly prolonged survival over mock or radioiodine only but the combination of virus with radioiodine was not more effective than virus alone. Iodine-131 105-116 solute carrier family 5 member 5 Homo sapiens 54-58 21989294-1 2011 BACKGROUND: Na+/I- symporter (NIS)-mediated iodide uptake allows radioiodine therapy for thyroid cancer. Iodine-131 65-76 solute carrier family 5 member 5 Homo sapiens 30-33 21801606-2 2011 Non-thyroid cancers can intake radioiodine after transfection of the human sodium iodide symporter (hNIS) gene. Iodine-131 31-42 solute carrier family 5 member 5 Homo sapiens 100-104 21797672-2 2011 In principle, undifferentiated thyroid cancers as well as nonthyroid cancers can concentrate and, thus, be treated with radioiodine after transfection with the human sodium iodide symporter (hNIS) gene. Iodine-131 120-131 solute carrier family 5 member 5 Homo sapiens 191-195 21797672-4 2011 METHODS: We used hTERT promoter-modulated expression of the hNIS and human thyroperoxidase (hTPO) genes in an experimental model of radioiodine-based treatment of malignant glioma. Iodine-131 132-143 solute carrier family 5 member 5 Homo sapiens 60-64 21499816-2 2011 Few data are available on the sodium/iodide symporter (NIS) expression in human testis, a particular important prerequisite to predict radioiodine accumulation in the gonads of males with thyroid cancer exposed to such a treatment. Iodine-131 135-146 solute carrier family 5 member 5 Homo sapiens 55-58 21801606-11 2011 These results demonstrated that radioiodine therapy was effective in treating malignant glioma cell lines following induction of tumor-specific iodide intake by the hTERT promoter-directed hNIS expression in vitro. Iodine-131 32-43 solute carrier family 5 member 5 Homo sapiens 189-193 21801606-12 2011 Co-transfected hNIS and hTPO genes can result in increased intake and longer retention of radioiodine. Iodine-131 90-101 solute carrier family 5 member 5 Homo sapiens 15-19 21471848-6 2011 RESULTS: Enhanced expression of NIS mRNA and protein was observed in FTC-133 cells treated with ATRA and tributyrin, which further resulted in significant higher levels of radioiodine uptake than that of untreated control cells and cells treated with ATRA alone. Iodine-131 172-183 solute carrier family 5 member 5 Homo sapiens 32-35 21531298-0 2011 Feasibility of a novel positive feedback effect of 131I-promoted Bac-Egr1-hNIS expression in malignant glioma via baculovirus. Iodine-131 51-55 solute carrier family 5 member 5 Homo sapiens 74-78 21531298-2 2011 As Egr1 promoter is activated by 131I and may promote human NIS (hNIS) expression, hNIS also induces 131I uptake and activates Egr1, so the existence of a positive feedback effect of 131I-promoted Egr1-hNIS expression is possible. Iodine-131 101-105 solute carrier family 5 member 5 Homo sapiens 83-87 21531298-5 2011 To test 131I-promoted hNIS expression, human malignant glioma U87 cells were transfected with Bac-Egr1-hNIS, stimulated with or without 131I; the expression of hNIS protein was detected by immunofluorescence and flow cytometry test. Iodine-131 8-12 solute carrier family 5 member 5 Homo sapiens 22-26 21531298-6 2011 In addition, the uptake and efflux of 131I were determined after the incubation of Bac-Egr1-hNIS-transfected U87 cells with or without 131I. Iodine-131 38-42 solute carrier family 5 member 5 Homo sapiens 92-96 21531298-11 2011 CONCLUSION: Our results indicated that an improved transgene expression of 131I-stimulated hNIS in U87 cells using a baculovirus vector containing the Egr1 promoter is possible, and the increased expression of hNIS is responsible for a higher 131I uptake. Iodine-131 75-79 solute carrier family 5 member 5 Homo sapiens 91-95 21531298-11 2011 CONCLUSION: Our results indicated that an improved transgene expression of 131I-stimulated hNIS in U87 cells using a baculovirus vector containing the Egr1 promoter is possible, and the increased expression of hNIS is responsible for a higher 131I uptake. Iodine-131 75-79 solute carrier family 5 member 5 Homo sapiens 210-214 21531298-11 2011 CONCLUSION: Our results indicated that an improved transgene expression of 131I-stimulated hNIS in U87 cells using a baculovirus vector containing the Egr1 promoter is possible, and the increased expression of hNIS is responsible for a higher 131I uptake. Iodine-131 243-247 solute carrier family 5 member 5 Homo sapiens 91-95 21531298-11 2011 CONCLUSION: Our results indicated that an improved transgene expression of 131I-stimulated hNIS in U87 cells using a baculovirus vector containing the Egr1 promoter is possible, and the increased expression of hNIS is responsible for a higher 131I uptake. Iodine-131 243-247 solute carrier family 5 member 5 Homo sapiens 210-214 21386735-0 2011 Feasibility of a novel positive feedback effect of 131I-promoted Bac-Egr1-hNIS expression in malignant glioma through baculovirus: a comparative study with Bac-CMV-hNIS. Iodine-131 51-55 solute carrier family 5 member 5 Homo sapiens 74-78 21386735-1 2011 OBJECTIVE: Increased expression of sodium iodide symporter (NIS) is required for reporter gene imaging and effective radioiodine treatment of tumor. Iodine-131 117-128 solute carrier family 5 member 5 Homo sapiens 60-63 21531298-1 2011 PURPOSE: As intracellular iodine is released rapidly, increased expression of sodium/iodide symporter (NIS) is required for effective radioiodine treatment of tumor. Iodine-131 134-145 solute carrier family 5 member 5 Homo sapiens 103-106 21531298-2 2011 As Egr1 promoter is activated by 131I and may promote human NIS (hNIS) expression, hNIS also induces 131I uptake and activates Egr1, so the existence of a positive feedback effect of 131I-promoted Egr1-hNIS expression is possible. Iodine-131 101-105 solute carrier family 5 member 5 Homo sapiens 83-87 21531298-2 2011 As Egr1 promoter is activated by 131I and may promote human NIS (hNIS) expression, hNIS also induces 131I uptake and activates Egr1, so the existence of a positive feedback effect of 131I-promoted Egr1-hNIS expression is possible. Iodine-131 101-105 solute carrier family 5 member 5 Homo sapiens 83-87 21531298-2 2011 As Egr1 promoter is activated by 131I and may promote human NIS (hNIS) expression, hNIS also induces 131I uptake and activates Egr1, so the existence of a positive feedback effect of 131I-promoted Egr1-hNIS expression is possible. Iodine-131 101-105 solute carrier family 5 member 5 Homo sapiens 83-87 20228127-1 2010 Radioiodine remains the only tumoricidal therapy for disseminated thyroid carcinomas; however, dedifferentiated tumors lose the expression of human sodium-iodide symporter (hNIS) gene, and cannot respond to this treatment. Iodine-131 0-11 solute carrier family 5 member 5 Homo sapiens 173-177 21209020-1 2011 Na(+)/I(-) symporter (NIS)-mediated iodide uptake into thyroid follicular cells serves as the basis of radioiodine therapy for thyroid cancer. Iodine-131 103-114 solute carrier family 5 member 5 Homo sapiens 0-20 20683361-1 2010 OBJECTIVE: Increased expression of sodium/iodide symporter (NIS) is required for reporter gene imaging and effective radioiodine treatment of tumor. Iodine-131 117-128 solute carrier family 5 member 5 Homo sapiens 60-63 21204761-13 2010 A combination hNIS mediated radioiodine gene therapy added to MDR1 shRNA treatment improved the effects of cancer treatment in a MDR cancer model and could enable visualization of the antitumor effects with nuclear imaging. Iodine-131 28-39 solute carrier family 5 member 5 Homo sapiens 14-18 20428214-2 2010 We have extended the use of NIS-mediated radioiodine therapy to other types of cancer, we transferred and expressed the NIS gene into prostate, colon and breast cancer cells using adenoviral vectors. Iodine-131 41-52 solute carrier family 5 member 5 Homo sapiens 28-31 20428214-2 2010 We have extended the use of NIS-mediated radioiodine therapy to other types of cancer, we transferred and expressed the NIS gene into prostate, colon and breast cancer cells using adenoviral vectors. Iodine-131 41-52 solute carrier family 5 member 5 Homo sapiens 120-123 20428214-6 2010 Radioiodine uptake was readily measurable in LnCaP cells infected with Ad5PB_RSV-NIS 24 h post-infection, confirming NIS expression. Iodine-131 0-11 solute carrier family 5 member 5 Homo sapiens 81-84 20428214-6 2010 Radioiodine uptake was readily measurable in LnCaP cells infected with Ad5PB_RSV-NIS 24 h post-infection, confirming NIS expression. Iodine-131 0-11 solute carrier family 5 member 5 Homo sapiens 117-120 21089675-6 2010 In vivo, Ad-CMV-NIS infected tumors showed significant radioiodine accumulation (16.30 +/- 8.72)% ID/g at 2h postinjection) with an effective half-life of 5.4h. Iodine-131 55-66 solute carrier family 5 member 5 Homo sapiens 16-19 20228127-2 2010 Previous studies suggested that a trans-active protein factor (NIS-repressor) represses endogenous hNIS transcription, likely contributing to the loss of radioiodine uptake, and defined the NIS-repressor binding site (NRBS) in the proximal hNIS promoter. Iodine-131 154-165 solute carrier family 5 member 5 Homo sapiens 63-66 20228127-2 2010 Previous studies suggested that a trans-active protein factor (NIS-repressor) represses endogenous hNIS transcription, likely contributing to the loss of radioiodine uptake, and defined the NIS-repressor binding site (NRBS) in the proximal hNIS promoter. Iodine-131 154-165 solute carrier family 5 member 5 Homo sapiens 99-103 20228127-2 2010 Previous studies suggested that a trans-active protein factor (NIS-repressor) represses endogenous hNIS transcription, likely contributing to the loss of radioiodine uptake, and defined the NIS-repressor binding site (NRBS) in the proximal hNIS promoter. Iodine-131 154-165 solute carrier family 5 member 5 Homo sapiens 100-103 20228127-2 2010 Previous studies suggested that a trans-active protein factor (NIS-repressor) represses endogenous hNIS transcription, likely contributing to the loss of radioiodine uptake, and defined the NIS-repressor binding site (NRBS) in the proximal hNIS promoter. Iodine-131 154-165 solute carrier family 5 member 5 Homo sapiens 240-244 20228127-9 2010 NIS-repressor, including its PARP-1 component, presents a potential therapeutic target to restore radioiodine uptake in dedifferentiated thyroid carcinomas. Iodine-131 98-109 solute carrier family 5 member 5 Homo sapiens 0-3 19098211-13 2009 Tumor xenografts infected with MV-NIS concentrated radioiodine, allowing serial quantitative imaging with (123)I micro-SPECT/CT. Iodine-131 51-62 solute carrier family 5 member 5 Homo sapiens 34-37 18500672-1 2009 The Na(+)/I(-) symporter (NIS) is a transmembrane glycoprotein that mediates iodide uptake into thyroid follicular cells and serves as the molecular basis of radioiodine imaging and therapy for thyroid cancer patients. Iodine-131 158-169 solute carrier family 5 member 5 Homo sapiens 4-24 18500672-1 2009 The Na(+)/I(-) symporter (NIS) is a transmembrane glycoprotein that mediates iodide uptake into thyroid follicular cells and serves as the molecular basis of radioiodine imaging and therapy for thyroid cancer patients. Iodine-131 158-169 solute carrier family 5 member 5 Homo sapiens 26-29 24899932-6 2010 In this article, we explain the relationship between NIS expression and the treatment of thyroid carcinoma with I-131, and we include a review of the results of our experimental and clinical trials. Iodine-131 112-117 solute carrier family 5 member 5 Homo sapiens 53-56 20053774-9 2010 Our findings suggest that hNIS radioiodine gene therapy can generate tumor-associated immunity in tumor microenvironments and enhance the killing activities of CTLs. Iodine-131 31-42 solute carrier family 5 member 5 Homo sapiens 26-30 19241193-0 2009 AFP promoter enhancer increased specific expression of the human sodium iodide symporter (hNIS) for targeted radioiodine therapy of hepatocellular carcinoma. Iodine-131 109-120 solute carrier family 5 member 5 Homo sapiens 90-94 19098211-16 2009 CONCLUSION: MV-NIS efficiently infects human pancreatic tumor cells and results in sufficient radioiodine uptake to enable noninvasive serial imaging and quantitation of the intensity, distribution, and time course of NIS gene expression. Iodine-131 94-105 solute carrier family 5 member 5 Homo sapiens 15-18 18165779-7 2007 RESULTS: Higher ex vivo radioiodine counts were noted in the hearts perfused with Ad-hNIS (1.04+/-0.2) compared to either the UW group (0.31+/-0.11, P<0.001) or the Ad-Null group (0.32+/-0.08, P<0.001). Iodine-131 24-35 solute carrier family 5 member 5 Homo sapiens 85-89 18986218-4 2008 Functional hNIS expression was confirmed by radioiodine uptake. Iodine-131 44-55 solute carrier family 5 member 5 Homo sapiens 11-15 19169486-8 2008 CONCLUSION: Our findings suggest that BRAF mutational status and decreased NIS and TSHR expression in this patient may reduce radioiodine uptake and lead to a negative response to radioiodine therapy. Iodine-131 126-137 solute carrier family 5 member 5 Homo sapiens 75-78 19169486-8 2008 CONCLUSION: Our findings suggest that BRAF mutational status and decreased NIS and TSHR expression in this patient may reduce radioiodine uptake and lead to a negative response to radioiodine therapy. Iodine-131 180-191 solute carrier family 5 member 5 Homo sapiens 75-78 18703598-15 2008 This study represents a promising first step in investigations of the potential use of a combination of the NIS gene and MDR1 shRNA as a new therapeutic strategy allowing RNA interference-based gene therapy, NIS-based radioiodine therapy, and in vivo monitoring based on NIS imaging. Iodine-131 218-229 solute carrier family 5 member 5 Homo sapiens 108-111 17980613-0 2008 Non-invasive radioiodine imaging for accurate quantitation of NIS reporter gene expression in transplanted hearts. Iodine-131 13-24 solute carrier family 5 member 5 Homo sapiens 62-65 17164311-2 2007 Dedifferentiated cells lose radioiodine uptake from human sodium-iodide symporter (hNIS) gene transcription failure consequent to genomic structure (chromatin compaction) and composition (CpG methylation). Iodine-131 28-39 solute carrier family 5 member 5 Homo sapiens 83-87 17891230-8 2007 In conclusion, NIS gene cloning led to an important development in the field of thyroid pathophysiology, and has also been fundamental to extend the use of radioiodine for the management of non-thyroid tumors. Iodine-131 156-167 solute carrier family 5 member 5 Homo sapiens 15-18 17639055-1 2007 The Na(+)/I(-) symporter (NIS)-mediated iodide uptake is the basis for targeted radioiodine ablation of thyroid cancers. Iodine-131 80-91 solute carrier family 5 member 5 Homo sapiens 4-24 17639055-1 2007 The Na(+)/I(-) symporter (NIS)-mediated iodide uptake is the basis for targeted radioiodine ablation of thyroid cancers. Iodine-131 80-91 solute carrier family 5 member 5 Homo sapiens 26-29 17332617-1 2007 UNLABELLED: Increased expression of the sodium iodide symporter (NIS) is required for effective radioiodine treatment and reporter gene imaging of breast cancer. Iodine-131 96-107 solute carrier family 5 member 5 Homo sapiens 65-68 17164311-4 2007 RESULTS: Combined 5-azacytidine and sodium butyrate restores hNIS gene transcription in KAK-1 to levels approaching radioiodine-treatable tumors. Iodine-131 116-127 solute carrier family 5 member 5 Homo sapiens 61-65 15611825-4 2004 Here we analyzed some of them, with emphasis on the expression of NIS, a determinant of prognosis since the functional integrity of the iodine transport is essential to assure an uptake of radioiodine high enough to detect and destroy any tumoral thyroid tissue. Iodine-131 189-200 solute carrier family 5 member 5 Homo sapiens 66-69 16644756-1 2006 UNLABELLED: We investigated the feasibility of radioiodine therapy targeting hepatoma cells (MH3924A) by tissue-specific expression of the human sodium/iodide symporter (hNIS) gene directed by the murine albumin enhancer and promoter (mAlb). Iodine-131 47-58 solute carrier family 5 member 5 Homo sapiens 170-174 16253762-2 2005 However, in thyroid carcinoma, down-regulated or mis-targeted NIS expression is commonly found and usually correlates with tumor dedifferentiation and loss of radioiodine uptake capacity. Iodine-131 159-170 solute carrier family 5 member 5 Homo sapiens 62-65 15941870-8 2005 In an in vitro clonogenic assay, 84% of NIS-transfected TT cells were killed by exposure to 131-I, whereas only about 0.6% of control cells were killed. Iodine-131 92-97 solute carrier family 5 member 5 Homo sapiens 40-43 15941870-10 2005 This study demonstrates the potential of NIS as a therapeutic gene, allowing radioiodine therapy of MTC after tissue-specific NIS gene transfer. Iodine-131 77-88 solute carrier family 5 member 5 Homo sapiens 41-44 17045167-8 2006 Thus, tRA treatment of human anaplastic thyroid carcinoma cells stably expressing the NIS gene significantly elevates their NIS-mediated radioiodine uptake and alters the expression of many genes involved in cell growth and cellular differentiation. Iodine-131 137-148 solute carrier family 5 member 5 Homo sapiens 86-89 17045167-8 2006 Thus, tRA treatment of human anaplastic thyroid carcinoma cells stably expressing the NIS gene significantly elevates their NIS-mediated radioiodine uptake and alters the expression of many genes involved in cell growth and cellular differentiation. Iodine-131 137-148 solute carrier family 5 member 5 Homo sapiens 124-127 15754731-1 2004 The functional role of the sodium iodide symporter (NIS) in extrathyroidal tissues was investigated by examining its mRNA and protein expression, together with the evidence of radioiodine (131)I uptake in 302 patients who underwent (131)I total body scanning, following the administration of high doses of (131)I for a papillary or follicular thyroid carcinoma. Iodine-131 176-187 solute carrier family 5 member 5 Homo sapiens 52-55 15671766-8 2004 In summary, NIS gene transfection to a single anaplastic thyroid cancer cell line efficiently triggered high tumor uptake of radioiodines, 99mTc and 188Re. Iodine-131 125-137 solute carrier family 5 member 5 Homo sapiens 12-15 12894520-11 2003 Using a clonogenic assay for monolayer culture, we demonstrated a 50-70% killing effect of 131I on DU145 cells expressing the NIS gene. Iodine-131 91-95 solute carrier family 5 member 5 Homo sapiens 126-129 12649158-7 2003 Transduction of myeloma cells with the targeted vector coding for the human sodiumiodide symporter (hNIS) led to hNIS expression by these cells allowing them to concentrate radioiodine up to 18-fold compared with controls. Iodine-131 173-184 solute carrier family 5 member 5 Homo sapiens 100-104 12649158-7 2003 Transduction of myeloma cells with the targeted vector coding for the human sodiumiodide symporter (hNIS) led to hNIS expression by these cells allowing them to concentrate radioiodine up to 18-fold compared with controls. Iodine-131 173-184 solute carrier family 5 member 5 Homo sapiens 113-117 14712300-1 2004 The sodium iodide symporter (NIS) mediates iodide uptake into thyrocytes and is the molecular basis of thyroid radioiodine therapy. Iodine-131 111-122 solute carrier family 5 member 5 Homo sapiens 29-32 14712300-2 2004 We previously have shown that NIS gene transfer into the F98 rat gliomas facilitated tumor imaging and increased survival by radioiodine. Iodine-131 125-136 solute carrier family 5 member 5 Homo sapiens 30-33 14633711-0 2003 Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer. Iodine-131 124-135 solute carrier family 5 member 5 Homo sapiens 106-109 14633711-2 2003 Adenovirus-mediated expression of NIS that is driven by prostate-specific promoters induces generous radioiodine accumulation in prostate cancer cells that may be used for therapy with (131)I. Iodine-131 101-112 solute carrier family 5 member 5 Homo sapiens 34-37 12894520-12 2003 The same dose of 131I resulted in complete death of tumor spheroids composed of the DU145-NIS cells. Iodine-131 17-21 solute carrier family 5 member 5 Homo sapiens 90-93 12390328-4 2002 In addition to its key function in thyroid physiology, NIS-mediated iodide accumulation allows diagnostic thyroid scintigraphy as well as effective therapeutic application of radioiodine in benign and malignant thyroid disease. Iodine-131 175-186 solute carrier family 5 member 5 Homo sapiens 55-58 12477251-6 2002 In addition, the tumor killing effects of 131I after NIS gene transfer have been demonstrated in in vitro clonogenic assays and in vivo radioiodide therapy studies, suggesting that NIS gene can also serve as a therapeutic agent when combined with radioiodide injection. Iodine-131 42-46 solute carrier family 5 member 5 Homo sapiens 53-56 12477251-6 2002 In addition, the tumor killing effects of 131I after NIS gene transfer have been demonstrated in in vitro clonogenic assays and in vivo radioiodide therapy studies, suggesting that NIS gene can also serve as a therapeutic agent when combined with radioiodide injection. Iodine-131 42-46 solute carrier family 5 member 5 Homo sapiens 181-184 11272095-1 2001 Decrease or loss of the sodium iodide (Na+/I-) symporter (NIS) activity influences the suitability of using radioiodine to detect and treat metastatic thyroid tissues. Iodine-131 108-119 solute carrier family 5 member 5 Homo sapiens 39-56 12192542-1 2002 At the molecular level, the uptake of radioiodine and pertechnetate is proportional to the expression of the thyroidal sodium/iodine symporter (NIS). Iodine-131 38-49 solute carrier family 5 member 5 Homo sapiens 144-147 11701745-1 2001 The ability of thyroid cancers to concentrate radioiodine (RAI) is dependent, in part, upon the expression and functional integrity of the sodium iodide symporter (NIS). Iodine-131 46-57 solute carrier family 5 member 5 Homo sapiens 164-167 11525275-2 2001 We report two such patients and demonstrate that the in vivo 131I uptake by the kidney metastasis is associated with high levels of sodium iodide (Na+/I-) symporter (NIS) expression in the first case. Iodine-131 61-65 solute carrier family 5 member 5 Homo sapiens 147-164 11396700-3 2001 Now that the molecule that mediates radioiodine uptake, the sodium iodide symporter (NIS), has been cloned and characterized, it may be possible to develop novel strategies to differentially modulate NIS expression and/or activity, enhancing it in target tissues and impeding it in others. Iodine-131 36-47 solute carrier family 5 member 5 Homo sapiens 85-88 11228531-1 2000 To evaluate the potential of the expression of the sodium/iodide symporter (NIS) as a means of targeting radioiodine to tumor cells, we have employed plasmid-mediated transfection of the NIS gene into a range of mammalian cell hosts. Iodine-131 105-116 solute carrier family 5 member 5 Homo sapiens 76-79 11228531-4 2000 After exposure of two-dimensional monolayer cultures of UVW-NIS cells to 131I- at a radioactive concentration of 4 MBq/mL, clonogenic survival was reduced to 21%. Iodine-131 73-78 solute carrier family 5 member 5 Homo sapiens 60-63 11079502-2 2000 To investigate the feasibility of 131I therapy for breast cancer, we established breast cancer cells stably expressing Na-/I- symporter (NIS) gene that can be modulated and studied in vitro and in vivo. Iodine-131 34-38 solute carrier family 5 member 5 Homo sapiens 119-135 11079502-2 2000 To investigate the feasibility of 131I therapy for breast cancer, we established breast cancer cells stably expressing Na-/I- symporter (NIS) gene that can be modulated and studied in vitro and in vivo. Iodine-131 34-38 solute carrier family 5 member 5 Homo sapiens 137-140 11079502-12 2000 CONCLUSION: Our preliminary data indicate that NIS-based gene therapy may be applied by concentrating a lethal dose of radiation in tumor cells in vivo, but further investigation is necessary to determine a method of maintaining radioiodine in the cells to allow greater therapeutic effects. Iodine-131 229-240 solute carrier family 5 member 5 Homo sapiens 47-50 24898835-1 2014 Approximately 30% of patients with advanced, metastatic differentiated thyroid cancer have radioiodine-refractory disease, based on decreased expression of the sodium iodide symporter SLC5A5 (NIS), diminished membrane targeting of NIS, or both. Iodine-131 91-102 solute carrier family 5 member 5 Homo sapiens 184-190 10576759-5 1999 NIS mRNA was also detected in non-thyroid tissues able to concentrate radioiodine, including salivary glands, stomach, thymus and breast. Iodine-131 70-81 solute carrier family 5 member 5 Homo sapiens 0-3 10576759-12 1999 The relationship between radioiodine uptake and NIS expression by thyroid cancer cells require further study. Iodine-131 25-36 solute carrier family 5 member 5 Homo sapiens 48-51 10232600-2 1999 Causing prostate cancer cells to express functionally active sodium iodide symporter (NIS) would enable those cells to concentrate iodide from plasma and might offer the ability to treat prostate cancer with radioiodine. Iodine-131 208-219 solute carrier family 5 member 5 Homo sapiens 86-89 9814499-14 1998 In three cancers with positive hNIS cells, the 131I scan showed uptake in lymph node metastases. Iodine-131 47-51 solute carrier family 5 member 5 Homo sapiens 31-35 9814499-15 1998 This suggests that immunodetection of hNIS could predict radioiodine uptake in thyroid cancers. Iodine-131 57-68 solute carrier family 5 member 5 Homo sapiens 38-42 24898835-1 2014 Approximately 30% of patients with advanced, metastatic differentiated thyroid cancer have radioiodine-refractory disease, based on decreased expression of the sodium iodide symporter SLC5A5 (NIS), diminished membrane targeting of NIS, or both. Iodine-131 91-102 solute carrier family 5 member 5 Homo sapiens 192-195 24898835-1 2014 Approximately 30% of patients with advanced, metastatic differentiated thyroid cancer have radioiodine-refractory disease, based on decreased expression of the sodium iodide symporter SLC5A5 (NIS), diminished membrane targeting of NIS, or both. Iodine-131 91-102 solute carrier family 5 member 5 Homo sapiens 231-234 33511173-2 2021 Lung cancers with NIS expression may uptake radioiodine (RAI) and show RAI-avid lesions on RAI scan for differentiated thyroid cancer (DTC) surveillance. Iodine-131 44-55 solute carrier family 5 member 5 Homo sapiens 18-21 34771624-0 2021 Analysis of NIS Plasma Membrane Interactors Discloses Key Regulation by a SRC/RAC1/PAK1/PIP5K/EZRIN Pathway with Potential Implications for Radioiodine Re-Sensitization Therapy in Thyroid Cancer. Iodine-131 140-151 solute carrier family 5 member 5 Homo sapiens 12-15 34771624-1 2021 The functional expression of the sodium-iodide symporter (NIS) at the membrane of differentiated thyroid cancer (DTC) cells is the cornerstone for the use of radioiodine (RAI) therapy in these malignancies. Iodine-131 158-169 solute carrier family 5 member 5 Homo sapiens 58-61 34771624-1 2021 The functional expression of the sodium-iodide symporter (NIS) at the membrane of differentiated thyroid cancer (DTC) cells is the cornerstone for the use of radioiodine (RAI) therapy in these malignancies. Iodine-131 171-174 solute carrier family 5 member 5 Homo sapiens 58-61 34771624-4 2021 However, there are many RAI-refractory DTCs in which the NIS mRNA and protein levels are relatively abundant but only reduced levels of iodide uptake are detected, suggesting a posttranslational failure in the delivery of NIS to the plasma membrane (PM), or an impaired residency at the PM. Iodine-131 24-27 solute carrier family 5 member 5 Homo sapiens 57-60 34771624-10 2021 Besides providing novel insights into the regulation of NIS localization and function at the PM of TC cells, our results open new venues for therapeutic intervention in TC, namely the possibility of modulating abnormal SRC signaling in refractory TC from a proliferative/invasive effect to the re-sensitization of these tumors to RAI therapy by inducing NIS retention at the PM. Iodine-131 330-333 solute carrier family 5 member 5 Homo sapiens 56-59 34771624-10 2021 Besides providing novel insights into the regulation of NIS localization and function at the PM of TC cells, our results open new venues for therapeutic intervention in TC, namely the possibility of modulating abnormal SRC signaling in refractory TC from a proliferative/invasive effect to the re-sensitization of these tumors to RAI therapy by inducing NIS retention at the PM. Iodine-131 330-333 solute carrier family 5 member 5 Homo sapiens 354-357 33831503-3 2021 However, in part of the patients, a reduction of the sodium-iodide symporter (NIS) occurs, rendering radioiodine therapy ineffective. Iodine-131 101-112 solute carrier family 5 member 5 Homo sapiens 78-81 34199867-11 2021 This study shows for the first time that miR-181a-5p directly regulates SLC5A5 expression in the context of PTC and may decrease efficacy of radioiodine treatment. Iodine-131 141-152 solute carrier family 5 member 5 Homo sapiens 72-78 33974556-3 2021 This NIS expression permits 131I accumulation and radiation damage in these non-target tissues, which accounts for the adverse effects of radioiodine therapy. Iodine-131 138-149 solute carrier family 5 member 5 Homo sapiens 5-8 26838744-1 2016 Radioiodine ablation (RIA) therapy is one of the most important treatments for papillary thyroid carcinoma (PTC), but some patients who received (131)I have radioiodine-refractory disease caused by the decreased expression of the Na(+)/I(-) symporter (NIS). Iodine-131 0-11 solute carrier family 5 member 5 Homo sapiens 230-250 31119602-9 2019 These data suggest that via inhibition of BCL-2 expression, overexpressed NES1 might enhance the effect of radiation therapy of 131I uptake in hNIS overexpressed PC3 cells. Iodine-131 128-132 solute carrier family 5 member 5 Homo sapiens 143-147 27363025-2 2016 Na+/I- symporter (NIS) expression in BCBMs would permit their selective targeting with radioiodide (131I-). Iodine-131 100-105 solute carrier family 5 member 5 Homo sapiens 0-16 33009242-3 2020 The sodium/iodide symporter (NIS) has positive expression in thyroid carcinomas with good prognoses and plays a critical role in radioiodine therapy response. Iodine-131 129-140 solute carrier family 5 member 5 Homo sapiens 29-32 31061881-0 2019 A Novel Chimeric Poxvirus Encoding hNIS Is Tumor-Tropic, Imageable, and Synergistic with Radioiodine to Sustain Colon Cancer Regression. Iodine-131 89-100 solute carrier family 5 member 5 Homo sapiens 35-39 31061881-10 2019 Finally, systemic delivery of radiotherapeutic I-131 isotope following CF33-hNIS infection of colon cancer xenografts enhances and sustains tumor regression compared with virus treatment alone in HCT116 xenografts, demonstrating synergy of oncolytic viral therapy with radioablation in vivo. Iodine-131 47-52 solute carrier family 5 member 5 Homo sapiens 76-80 29467904-11 2018 U87-hNIS cells also exhibited increased 131I retention in vivo; however, as the time increased, 131I was rapidly released with the tumor no longer able to be imaged 24 h after 131I injection. Iodine-131 40-44 solute carrier family 5 member 5 Homo sapiens 4-8 29467904-11 2018 U87-hNIS cells also exhibited increased 131I retention in vivo; however, as the time increased, 131I was rapidly released with the tumor no longer able to be imaged 24 h after 131I injection. Iodine-131 96-100 solute carrier family 5 member 5 Homo sapiens 4-8 29467904-11 2018 U87-hNIS cells also exhibited increased 131I retention in vivo; however, as the time increased, 131I was rapidly released with the tumor no longer able to be imaged 24 h after 131I injection. Iodine-131 96-100 solute carrier family 5 member 5 Homo sapiens 4-8 29298843-2 2018 The incorporation of radioiodine by cancer cells is mediated by sodium iodide symporter (NIS) (codified by the SLC5A5 gene), that is functional only when targeted to the cell membrane. Iodine-131 21-32 solute carrier family 5 member 5 Homo sapiens 89-92 29298843-2 2018 The incorporation of radioiodine by cancer cells is mediated by sodium iodide symporter (NIS) (codified by the SLC5A5 gene), that is functional only when targeted to the cell membrane. Iodine-131 21-32 solute carrier family 5 member 5 Homo sapiens 111-117 28386277-1 2017 Radioiodine whole body scan (WBS), related to sodium iodide symporter (NIS) function, is widely used to detect recurrence/metastasis in postoperative patients with thyroid cancer. Iodine-131 0-11 solute carrier family 5 member 5 Homo sapiens 71-74 26838744-1 2016 Radioiodine ablation (RIA) therapy is one of the most important treatments for papillary thyroid carcinoma (PTC), but some patients who received (131)I have radioiodine-refractory disease caused by the decreased expression of the Na(+)/I(-) symporter (NIS). Iodine-131 157-168 solute carrier family 5 member 5 Homo sapiens 230-250 25955347-0 2015 Effect of sodium/iodide symporter (NIS)-mediated radioiodine therapy on estrogen receptor-negative breast cancer. Iodine-131 49-60 solute carrier family 5 member 5 Homo sapiens 35-38 26397139-1 2015 Targeted radioiodine therapy for thyroid cancer is based on selective stimulation of Na+/I- Symporter (NIS)-mediated radioactive iodide uptake (RAIU) in thyroid cells by thyrotropin. Iodine-131 9-20 solute carrier family 5 member 5 Homo sapiens 85-101 25960292-0 2015 Inhibition of miR-146b expression increases radioiodine-sensitivity in poorly differential thyroid carcinoma via positively regulating NIS expression. Iodine-131 44-55 solute carrier family 5 member 5 Homo sapiens 135-138 25960292-6 2015 Fortunately, it was confirmed that miR-146b could regulate NIS expression/activity; what is more important, miR-146b interference would contribute to the recovery of radioiodine-sensitivity in dedifferentiated cells via positively regulating NIS. Iodine-131 166-177 solute carrier family 5 member 5 Homo sapiens 59-62 25960292-6 2015 Fortunately, it was confirmed that miR-146b could regulate NIS expression/activity; what is more important, miR-146b interference would contribute to the recovery of radioiodine-sensitivity in dedifferentiated cells via positively regulating NIS. Iodine-131 166-177 solute carrier family 5 member 5 Homo sapiens 242-245 26599396-0 2015 Glycosylation of Sodium/Iodide Symporter (NIS) Regulates Its Membrane Translocation and Radioiodine Uptake. Iodine-131 88-99 solute carrier family 5 member 5 Homo sapiens 42-45 26599396-7 2015 Functional activity of hNIS was estimated by radioiodine uptake. Iodine-131 45-56 solute carrier family 5 member 5 Homo sapiens 23-27 26599396-10 2015 RESULTS: cAMP-mediated Glycosylation of NIS resulted in increased expression of hNIS, stimulating membrane translocation, and enhanced radioiodine uptake. Iodine-131 135-146 solute carrier family 5 member 5 Homo sapiens 40-43 26599396-11 2015 In contrast, inhibition of glycosylation by treatment with tunicamycin dramatically reduced membrane translocation of intracellular hNIS, resulting in reduced radioiodine uptake. Iodine-131 159-170 solute carrier family 5 member 5 Homo sapiens 132-136 26599396-14 2015 Therefore, enhancing functional NIS by the increasing level of glycosylation may be suggested as a promising therapeutic strategy for cancer patients who show refractory response to conventional radioiodine treatment. Iodine-131 195-206 solute carrier family 5 member 5 Homo sapiens 32-35 25955347-5 2015 Functional NIS activity in the MDA-hNIS cells was confirmed by the uptake of 131I and cytotoxicity assays. Iodine-131 77-81 solute carrier family 5 member 5 Homo sapiens 11-14 24835528-1 2014 MV-NIS is an engineered measles virus that is selectively destructive to myeloma plasma cells and can be monitored by noninvasive radioiodine imaging of NIS gene expression. Iodine-131 130-141 solute carrier family 5 member 5 Homo sapiens 3-6 25615643-8 2015 RESULTS: 131I uptake was higher in CNE-2-hNIS than in CNE-2 cells. Iodine-131 9-13 solute carrier family 5 member 5 Homo sapiens 41-45 25773964-1 2015 The function of membrane-localized sodium iodide symporter (NIS) determines the efficacy of radioiodine therapy in thyroid cancer. Iodine-131 92-103 solute carrier family 5 member 5 Homo sapiens 60-63 25309780-5 2014 In this article, we describe the relationship between NIS expression and the thyroid carcinoma treatment using I-131 and alternative therapeutic approaches. Iodine-131 111-116 solute carrier family 5 member 5 Homo sapiens 54-57 24708099-2 2014 NIS is clinically very relevant because it allows the treatment with radioiodine of thyroid cancer patients. Iodine-131 69-80 solute carrier family 5 member 5 Homo sapiens 0-3 25410753-1 2015 Malignant glioma can be treated with radioiodine following transfection with human sodium iodide symporter (hNIS) gene. Iodine-131 37-48 solute carrier family 5 member 5 Homo sapiens 108-112 24835528-1 2014 MV-NIS is an engineered measles virus that is selectively destructive to myeloma plasma cells and can be monitored by noninvasive radioiodine imaging of NIS gene expression. Iodine-131 130-141 solute carrier family 5 member 5 Homo sapiens 153-156 24835528-5 2014 Tumor targeting was clearly documented by NIS-mediated radioiodine uptake in virus-infected plasmacytomas. Iodine-131 55-66 solute carrier family 5 member 5 Homo sapiens 42-45 24884806-1 2014 BACKGROUND: Expression and function of sodium iodide symporter (NIS) is requisite for efficient iodide transport in thyrocytes, and its presence in cancer cells allows the use of radioiodine as a diagnostic and therapeutic tool in thyroid neoplasia. Iodine-131 179-190 solute carrier family 5 member 5 Homo sapiens 64-67 24884806-4 2014 Moreover, stimulation of endogenous NIS expression may permit the radioiodine treatment of extrathyroidal lesions by concentrating this radioisotope. Iodine-131 66-77 solute carrier family 5 member 5 Homo sapiens 36-39 24353283-1 2014 The TSH receptor (TSHR) and sodium/iodide symporter (NIS) are key players in radioiodine-based treatment of differentiated thyroid cancers. Iodine-131 77-88 solute carrier family 5 member 5 Homo sapiens 53-56 24369144-1 2014 Radioiodine therapy, the most effective form of systemic radiotherapy available, is currently useful only for thyroid cancer because of the thyroid-specific expression of the human sodium iodide symporter (hNIS). Iodine-131 0-11 solute carrier family 5 member 5 Homo sapiens 206-210 24369144-10 2014 These results show prostate-specific expression of the hNIS gene delivered by the PSMA promoter and effective radioiodine therapy of CRPC by the PSMA promoter-driven hNIS transfection. Iodine-131 110-121 solute carrier family 5 member 5 Homo sapiens 166-170 23038026-3 2013 Human hepatocellular carcinoma cells (HuH7) infected with Ad5-E1/AFP-E3/NIS concentrated radioiodine at a level that was sufficiently high for a therapeutic effect in vitro. Iodine-131 89-100 solute carrier family 5 member 5 Homo sapiens 72-75